World Female Contraceptive Market - 3.48% CAGR to 2020 adds Global Female Contraceptive Market 2016-2020 latest research report, this analyst forecast the global female contraceptive market to grow at a CAGR of 3.48% during the period 2016-2020.

The global female contraceptive market analyst says female contraceptives such as birth control pills are generally consumed to prevent pregnancy. However, their consumption has increased over time for other purposes other than avoiding pregnancy. In 2013, 1.5 million women globally used oral contraceptive pills for non-contraceptive benefits, like relief from menstrual pain, polycystic ovarian disease, reduction of acne, and regulation of the menstrual cycle.

Complete report on female contraceptive market spread across 78 pages, analyzing 4 major companies and providing 46 data exhibits are now available at

According to the female contraceptive market report, innovation and effectiveness of female contraceptives constitute the key to market growth. Several vendors are entering into strategic alliances and investing in R&D for product innovation and better financial stability, thereby developing the latest products with better efficiency, safety, and protection. These strategic decisions help companies generate revenue and acquire a significant share of the female contraceptive market.

The following companies are the key players in the global female contraceptive market: Allergan, Merck Millipore, Pfizer, and Teva. Other prominent vendors in the market are: Afaxys, Agile Therapeutics, Ansell, Bayer Pharma, Caya, Ferring Pharmaceuticals, Female Health, Fuji Latex, HLL Lifecare, Janssen Pharmaceuticals, Lipocine, Lupin Pharmaceuticals, Mayer Laboratories, Okamoto Industries, Reckitt Benckiser, Syzygy Healthcare, and V-Care Pharma. Order a copy of Global Female Contraceptive Market 2016-2020 report @

The female contraceptive market was led by the devices segment during 2015 and will continue its dominance throughout the forecast period. The segment is predominantly driven by the continuous introduction of new devices with increased reliability and better outcomes. IUDs are the most accepted form of long-acting reversible contraception in this segment. For instance, IUDs prolong pregnancy time by three years, and subdermal implants delay the pregnancy from one to five years. Moreover, the improved distribution channels are offering flexibility to the consumers to opt for contraceptive devices based on their convenience and requirement.

The Americas dominated the female contraceptive market during 2015 owing to increased social acceptability of female contraceptives. Much of the region’s growth is also due to the presence of several vendors who are constantly introducing new and innovative products with enhanced properties. Also, the easy availability of advanced female contraceptive devices such as IUDs, subdermal implants, and diaphragms will be another growth factor for the growth of the market in this region. The most common female contraceptive used by Americans is the birth control pill, followed by the emergency pill, sterilization, IUD, and the vaginal ring.

Global Female Contraceptive Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the present scenario and the growth prospects of the global female contraceptive market for 2016-2020. To calculate the market size, the report considers the revenue generated from the overall retail sales of female contraceptive products globally.

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: ReportsnReports
Phone: 1 888 391 5441

Release ID: 144193